Clovis Seeks FDA Approval for Rubraca as Ovarian Cancer Maintenance Therapy

Clovis Seeks FDA Approval for Rubraca as Ovarian Cancer Maintenance Therapy
Clovis Oncology seeks to expand its approval for Rubraca (rucaparib) to include maintenance therapy for women with recurrent ovarian cancer who respond to platinum-based chemotherapy. The company, based in Boulder, Colorado, has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and plans to seek similar approval from the

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *